Table 3. Summary of miRNAs with altered expression, their validated targets and pathways entered this study.

miRNA	Reference	Expression	Potential target	Pathway
10b	[35–38]	Up	None	Cell invasion
17-5p	[39–41]	Up	PTEN,RBL2	Cell cycle, invasion and proliferation
21	[4–8,43–60]	Up	BTG2,FASL,PDCD4,SPRY2	Cell apopsotis, chemoresistance, cycle, proliferation, FASL/FAS, MAPK/ERK and PI3K/AKT signaling
23a	[50, 53, 61, 62]	Up	ESRP1,FOXP2,NEDD4L	Cell invasion, epithelial-mesenchymal transition, migration and proliferation
29c	[33, 46, 69, 70]	Down	MMP2	Cell invasion, migration and Wnt signaling
126	[27, 68, 82]	Down	None	None
155	[14, 50, 51]	Up	None	None
196a	[16,17]	Up	None	None
200c	[109–111]	Unstable	None	Cell invasion and proliferation
203	[59, 112–114]	Up	None	None
218	[121–123]	Down	UGT8,VOPP1	Cell proliferation
221	[46, 50, 125, 126]	Up	None	Cell migration and proliferation
222	[28, 126, 127]	Up	NOSTRIN	None
451a	[7, 8, 23]	Up	None	None
1290	[24, 26]	Up	None	None

PTEN: phosphatase and tensin homolog; RBL2: RB transcriptional corepressor like 2; BTG2: BTG anti-proliferation factor 2; FASL: Fas ligand; PDCD4: programmed cell death 4; SPRY2: sprouty RTK signaling antagonist 2; ESRP1: epithelial splicing regulatory protein 1; FOXP2: forkhead box P2; NEDD4L: NEDD4 like E3 ubiquitin protein ligase; UGT8: UDP glycosyltransferase 8; VOPP1: VOPP1 WW domain binding protein; NOSTRIN: nitric oxide synthase trafficking; FAS: Fas cell surface death receptor; MAPK: mitogen-activated protein kinase; ERK: extracellular regulated protein kinases; PI3K: phosphoinositide-3-kinase; AKT: AKT serine/threonine kinase 1.